دورية أكاديمية

Inhibition of arginase modulates T-cell response in the tumor microenvironment of lung carcinoma

التفاصيل البيبلوغرافية
العنوان: Inhibition of arginase modulates T-cell response in the tumor microenvironment of lung carcinoma
المؤلفون: Anna Sosnowska, Justyna Chlebowska-Tuz, Pawel Matryba, Zofia Pilch, Alan Greig, Artur Wolny, Tomasz M. Grzywa, Zuzanna Rydzynska, Olga Sokolowska, Tomasz P. Rygiel, Marcin Grzybowski, Paulina Stanczak, Roman Blaszczyk, Dominika Nowis, Jakub Golab
المصدر: OncoImmunology, Vol 10, Iss 1 (2021)
بيانات النشر: Taylor & Francis Group, 2021.
سنة النشر: 2021
المجموعة: LCC:Immunologic diseases. Allergy
LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
مصطلحات موضوعية: arginase, tumor microenvironment, immunosuppression, arginase inhibitor, immunotherapy, t-cells response, myeloid cells, Immunologic diseases. Allergy, RC581-607, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
الوصف: Immunotherapy has demonstrated significant activity in a broad range of cancer types, but still the majority of patients receiving it do not maintain durable therapeutic responses. Amino acid metabolism has been proposed to be involved in the regulation of immune response. Here, we investigated in detail the role of arginase 1 (Arg1) in the modulation of antitumor immune response against poorly immunogenic Lewis lung carcinoma. We observed that tumor progression is associated with an incremental increase in the number of Arg1+ myeloid cells that accumulate in the tumor microenvironment and cause systemic depletion of ʟ-arginine. In advanced tumors, the systemic concentrations of ʟ-arginine are decreased to levels that impair the proliferation of antigen-specific T-cells. Systemic or myeloid-specific Arg1 deletion improves antigen-induced proliferation of adoptively transferred T-cells and leads to inhibition of tumor growth. Arginase inhibitor was demonstrated to modestly inhibit tumor growth when used alone, and to potentiate antitumor effects of anti-PD-1 monoclonal antibodies and STING agonist. The effectiveness of the combination immunotherapy was insufficient to induce complete antitumor responses, but was significantly better than treatment with the checkpoint inhibitor alone. Together, these results indicate that arginase inhibition alone is of modest therapeutic benefit in poorly immunogenic tumors; however, in combination with other treatment strategies it may significantly improve survival outcomes.
نوع الوثيقة: article
وصف الملف: electronic resource
اللغة: English
تدمد: 2162-402X
2162402X
Relation: https://doaj.org/toc/2162-402X
DOI: 10.1080/2162402X.2021.1956143
URL الوصول: https://doaj.org/article/07d158283324431ba6734d685c57a6a0
رقم الأكسشن: edsdoj.07d158283324431ba6734d685c57a6a0
قاعدة البيانات: Directory of Open Access Journals
الوصف
تدمد:2162402X
DOI:10.1080/2162402X.2021.1956143